Biogen Inc. made a dramatic price cut on its new Alzheimer’s disease treatment called Aduhelm after the product launch got off to a slow start. It’s still expensive, even after the company cut the price of the drug almost in half, from a $56K annual cost to $28K. Aduhelm is the first new treatment for Alzheimer’s disease in almost too decades. “Too many patients are not being offered the choice of Aduhelm due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer’s disease,” said Biogen CEO Michel Vounatsos.
